Disinfection Robots Market Growing at a CAGR of 30.1% to Reach 2.79 Billion by 2028

 In its latest publication on the disinfection robots market, Meticulous Research®, states that the global disinfection robots market is expected to grow at a CAGR of 30.1% from 2021 to 2028 to reach $2.79 billion.

This market is driven by the increasing prevalence of hospital-acquired infections and the advantages offered by disinfection robots over manual disinfection. Furthermore, emerging economies and technological advancements in the field of robotics are expected to provide the industry with significant potential prospects in the future. However, the limitations of disinfection robots may hinder the growth of this market. Also, the high initial investment coupled with additional repair & maintenance costs poses a major challenge for the growth of this market.

Get Inside Scoop Of The Report, Download For Free Sample PDF @ https://www.meticulousresearch.com/download-sample-report/cp_id=5234

To provide efficient analysis, Meticulous Research® has segmented this market based on type, technology, end user, and geography. The study also evaluates industry competitors and analyzes the market at the country level.

In 2021, based on type, the ultraviolet light disinfection robots segment is estimated to account for the largest share of the market. The large market share of this segment is attributed to the advantages of ultraviolet light disinfection robots in disinfecting hospital rooms with great efficiency and minimal need for manual intervention.

Request Sample Report: https://www.meticulousresearch.com/request-sample-report/cp_id=5234

In 2021, based on technology, the fully autonomous disinfection robots segment is estimated to account for the largest share of the overall market. The large market share of this segment is attributed to the technologically advanced features of fully autonomous disinfection robots, with self-navigation and smart decision-making capabilities.

The report provides competitive intelligence in terms of financials, growth strategies, type, technology, end user, and geographical presence on some of the key players in this market, including SESTO Robotics Pte. Ltd. (Singapore), UVD Robots (Denmark), PDI, Inc. (U.S.), Xenex Disinfection Services Inc. (U.S.), Nevoa Inc. (U.S.), Badger Technologies LLC (U.S.), Skytron, LLC (U.S.), Omron Corporation (Japan), Fetch Robotics, Inc. (U.S.), Finsen Technologies Ltd (U.K.), Taimi Robotics Technology Co. Ltd (China), Akara Robotics Ltd. (Ireland), Siemens AG (Germany), and Milagrow Business & Knowledge Solutions (Pvt.) Limited (India).

Speak to our Analysts to Understand the In Detail Impact of COVID-19 on Your Business: https://www.meticulousresearch.com/speak-to-analyst/cp_id=5234

Plasma Fractionation Market Worth $46.9 Billion by 2029

 

 

According to a new market research report, “Plasma Fractionation Market by Product [Immunoglobulins (Intravenous, Subcutaneous), Coagulation Factors, Albumin], Application (Immunology, Hematology, Neurology), and End User (Hospital, Clinical Research Lab, Academic Institutes) — Global Forecast to 2029”, published by Meticulous Research®, the plasma fractionation market is expected to grow at a CAGR of 7.1% from 2022 to reach $46.9 billion by 2029.

Download Free Sample Report Now @ https://www.meticulousresearch.com/download-sample-report/cp_id=5117

Some of the key players operating in this market are CSL Limited (Australia), Grifols, S.A. (Spain), Octopharma AG (Switzerland), Kedrion S.P.A. (Italy), Shire plc (U.K.), Biotest AG (Germany), China Biologic Products Holdings, Inc. (China), Bio Products Laboratory Ltd (U.K.), Japan Blood Products Organization (Japan), and Intas Pharmaceuticals Ltd. (India).

The report also includes an extensive assessment of the product portfolio, geographic analysis, and key strategic developments in the industry’s leading market participants over the past four years (2019–2022). In recent years, the plasma fractionation market has witnessed several product approvals, new product launches, partnerships, agreements, & collaborations, expansions, and acquisitions. For instance, in February 2022, Grifols, S.A. (Spain) entered into an agreement with Endpoint Health, Inc. (U.S.) to develop and commercialize an Antithrombin III (AT-III) therapy to treat Sepsis. Also, in August 2021, Octopharma AG (Switzerland) received U.S. FDA approval for Octagam 10% [Immune Globulin Intravenous (Human)] for the treatment of adult dermatomyositis (DM).

To gain more insights into the market with a detailed table of content and figures, click here: https://www.meticulousresearch.com/product/plasma-fractionation-market-5117

Scope of the Report:

Plasma Fractionation Market, by Product

• Immunoglobulins
• Intravenous Immunoglobulins
• Subcutaneous Immunoglobulins
• Intramuscular Immunoglobulins
•  
• Coagulation Factors
• Albumin
• Protease Inhibitors
• Others

Note: Other plasma-derived products include fibrin, sealant, and plasma.

Plasma Fractionation Market, by Application

• Immunology
• Hematology
• Neurology
• Critical Care
• Hemato-Oncology
• Rheumatology
• Others

Note: Other applications include management of respiratory diseases and wound healing.

Plasma Fractionation Market, by End User

• Hospitals& Clinics
• Clinical Research Laboratories
• Academic Institutes

Plasma Fractionation Market, by Geography

• North America
• U.S.
• Canada
•  
• Europe
• Germany
• France
• U.K.
• Italy
• Spain
• Rest of Europe (RoE)
•  
• Asia-Pacific (APAC)
• China
• Japan
• India
• Rest of APAC (RoAPAC)
•  
• Latin America
• Middle East & Africa

Download Free Sample Report Now @ https://www.meticulousresearch.com/download-sample-report/cp_id=5117